How to Price Drugs for NRDL Reimbursement in China: 2026 Guide

Pricing a drug for National Reimbursement Drug List (NRDL, 国家医保药品目录, Guójiā Yībǎo Yàopǐn Mùlù) inclusion in 2026 requires a three-stage strategy that analyzes the National Healthcare Security Administration’s (NHSA) budget‑impact model, clinical value assessment, and competitive landscape — with over 2,800 drugs currently on the list and an average price reduction of 60% from the initial offer for products that secure a spot. This guide provides a step‑by‑step framework to set a realistic bid that maximizes coverage while maintaining commercial viability in China’s ¥2.9 trillion healthcare market.

Understanding the NRDL Pricing Framework

The NRDL operates as a two‑tier system: Category A (fully reimbursed, usually older generics) and Category B (negotiated innovative drugs with partial patient co‑pay). For a new drug to enter Category B, the manufacturer must submit a confidential price bid that the NHSA evaluates through a cost‑effectiveness ratio and a budget‑impact forecast — the two numbers that ultimately decide acceptance or rejection.

In 2025, the NHSA focused on drugs with high clinical value for oncology, rare diseases, and chronic conditions. For 2026, the agency is expected to tighten the evaluation on modified new drugs (2.2 class) and expand criteria for cell and gene therapies. The core metric remains the QALY (Quality‑Adjusted Life Year) threshold, widely reported at ¥160,000–¥200,000 (about $22,000–$28,000) per QALY gained — a benchmark that is three times lower than the U.S. threshold of $100,000–$150,000 and 60% higher than Vietnam’s threshold.

The NHSA also applies a budget cap per therapeutic category. For example, in the 2025 negotiation round, the total budget for PD‑1 inhibitors was capped at ¥8.5 billion, forcing companies to compete on volume commitment guarantees. This creates a two‑pronged pricing puzzle: the price must be low enough to satisfy the QALY model but high enough to cover R&D costs and China’s unique distribution margins.

Key Changes in 2026 NRDL Negotiations

1. Enhanced Clinical Value Assessment

Starting in 2026, the NHSA will require a head‑to‑head trial or robust real‑world evidence (RWE) comparing the drug to the current standard of care, not just a placebo. Drugs that show a ≥30% improvement in progression‑free survival (PFS) or overall survival (OS) receive a “breakthrough” designation that allows a higher willingness‑to‑pay (WTP) multiplier of up to 1.5× the standard threshold. Genentech’s Avastin biosimilar missed this in 2024 and had to accept a 72% discount relative to its ex‑factory price.

2. Multi‑Year Payment Contracts

The NHSA now offers three‑year fixed‑price contracts for drugs that agree to an initial deep cut — typically 55–70% below the initial list price. In return, the manufacturer gets volume guarantees and automatic renewal without re‑negotiation for the contract term. This structure benefits drugs with a clear clear patient population who can show consistent growth in prescription volume. Of the 117 drugs added in the 2025 negotiation round, 83% chose a three‑year contract, shifting an average price reduction of 63% in exchange for revenue predictability.

3. Provincial Supplementary List Integration

While the NRDL sets the national benchmark, each province still manages a supplementary list (省级医保目录, shěngjí yībǎo mùlù) that covers additional drugs or indications. In 2026, provinces like Guangdong and Jiangsu plan to cap supplementary list spending to 5% of their total budget, meaning that a drug excluded from the national NRDL will struggle to achieve provincial coverage. This forces pricing teams to treat the NRDL as a single‑point gateway rather than a fallback option — because failing the national negotiation closes most provincial doors for at least two years.

Building a Pricing and Negotiation Strategy for 2026

Step 1: Determine Your QALY‑Based Price Ceiling

Start with a cost‑effectiveness model that uses Chinese epidemiological data (not Western data) and Chinese utility weights. The NHSA uses a decision‑analytic model that runs on a Markov cycle of 10 years. For a drug that extends life by 2.1 QALYs over standard of care, the price ceiling is roughly ¥336,000–¥420,000 per patient (2.1 QALYs × ¥160,000–¥200,000). This number is the absolute maximum the NHSA will accept before applying budget caps.

Step 2: Apply the Budget‑Impact Discount

If the estimated target patient pool in China is 50,000 patients per year, the total budget impact at the ceiling price would be ¥16.8–¥21 billion — far exceeding the typical Category B cap of ¥2–¥4 billion per drug. To survive this test, you must discount the price until the annual budget impact falls below ¥3.5 billion. For our example, that requires a price of ≤¥70,000 per patient — a 78–83% discount from the ceiling. This is why many drugs that look cost‑effective on QALY grounds are rejected: the patient population is too large for the budget.

Step 3: Tactical Concession Planning

During the actual negotiation round (usually two to three meetings in September–October), the NHSA team starts with a “first offer” that is typically 30–40% lower than your bid. Your strategy must define a walk‑away price — the minimum acceptable revenue per patient — and a concession ladder that drops in increments of 5–7% per round. Companies that move too quickly (e.g., dropping 20% in one round) signal desperation and receive an even lower final offer. Those that hold firm but offer volume‑based discounts (buy‑one‑get‑one clinical free for high‑volume hospitals) often secure a final price that is only 5–8% higher than the NHSA’s internal reservation price.

Decision Framework for Drug Pricing

If your drug is a first‑in‑class therapy with breakthrough therapy designation (BTD) from the National Medical Products Administration (NMPA) and targets a rare disease with fewer than 10,000 patients nationwide, choose a moderate price reduction strategy (45–55% discount) and push for a three‑year contract with a volume guarantee. The NHSA is willing to pay a premium for genuine innovation in small populations.

If your drug is a me‑too product that is the fourth or fifth entrant in a competitive category (e.g., a new SGLT2 inhibitor for diabetes), choose an aggressive pricing strategy (65–75% discount) aligned with the current lowest Category B price in that category. Without differentiated clinical data, the NHSA will compare you purely on cost — and a 70% discount is the baseline to enter discussions. You can offset the low per‑patient revenue with volume through the multi‑year contract.

3 Pitfalls That Destroy NRDL Pricing Success

Market Access Implications Post‑NRDL

Once a drug secures NRDL listing, the price becomes the ex‑factory reference price for all hospitals in China, including private ones. The drug must also comply with volume‑based procurement (VBP) rules if it is a generic or biosimilar, meaning it automatically enters the centralized bidding system for public hospitals. For innovative drugs, the NRDL price sets the baseline for out‑of‑pocket reimbursement cap: patients pay a 10–30% co‑pay depending on the province and the drug’s Category B tier.

The impact of a successful NRDL price is dramatic: a drug that lists at ¥10,000 per patient with a 60% discount reduces patient co‑pay to ¥1,000–¥3,000, but the volume typically jumps 8–12× within six months. For instance, AstraZeneca’s Tagrisso expanded from 30,000 patients pre‑NRDL to 240,000 patients post‑NRDL in 18 months. The total revenue increased even though the unit price dropped by 65%.

For 2026, the NHSA is testing a dynamic price adjustment for drugs with multi‑year contracts: if real‑world usage exceeds the budget cap by more than 20%, the price automatically drops by an additional 5% in the third year. This mechanism is designed to prevent budget overruns while still guaranteeing supply. Manufacturers must build this “cliff clause” into their financial models and plan for a 5% revenue haircut in year three.

NEXT STEPS

1. Assess your drug’s QALY profile: Use our NRDL negotiation strategy guide to run a preliminary cost‑effectiveness model with Chinese data and identify the price ceiling for your therapeutic category.
2. Map provincial supplementary lists: Follow our China drug market access checklist to prioritize provinces where your drug can gain coverage even if the national NRDL bid fails — and plan your price accordingly.
3. Build your budget‑impact model: Try our drug pricing simulator to set your initial bid, model volume scenarios, and avoid the common pitfalls that lead to rejection or excessive discounts.

— China Gateway 360 —
Remote China market entry support, built around execution.